Un-Answered Inquiries Around Opaganib Exposed

We also included an assessment of disease progression, the impact of equol production, and adverse events. Meta-analyses were performed where possible. All the studies were of good quality, with predominantly low risk of bias. The doses used in the included trials were generally consistent with those delivered by a typical Japanese soy-based diet (25�C100?mg soy isoflavones/day) [42], and estimates of daily genistein consumption delivered by soy-based diets (0.25�C1.0?mg/kg) [43]. Limitations of the present study include the fact that not all the studies included all endpoints, so most of our conclusions are based on subset analyses. In addition, with the exception of surveillance patients, studies did not stratify patients according to whether they were at low or high risk; thus, the ability of soy to modify http://www.selleckchem.com/products/abc294640.html progression based on biology (aggressive or non-aggressive) could not be assessed. Publication bias cannot be excluded, especially for studies conducted before the http://www.selleck.cn/products/ON-01910.html introduction of prospective trial registration. In the meta-analyses, end-of-treatment scores rather than change scores were used, which meant differences from baseline were not captured. Heterogeneity of soy/soy isoflavone preparations, dosage regimens and study populations among the studies suggest that the results of the meta-analyses should be interpreted with caution. Sample sizes in most studies were small; http://www.selleckchem.com/products/loxo-101.html except for one. The observed effects were smaller than anticipated in the three studies performing power analyses, suggesting some studies may have been underpowered. The duration of most studies was ��6 months only the largest study continued for 12 months. This raises the question of whether the duration of most studies was sufficient to detect clinically meaningful changes in the endpoints of interest, as progression from prostatic intraepithelial neoplasia to HGPIN and early latent cancer may take 10 or more years, and clinically significant carcinoma may not occur for another 3�C15 years [28], while recurrent disease may take a decade or more to become manifest [44]. Measuring PSA over short durations, as in these studies, may therefore be of limited value. The meta-analyses performed in the present review combined studies administering soy isoflavones in a variety of forms; however, there is evidence suggesting that the type of soy product may influence outcomes. In a meta-analysis of epidemiological studies on PCa risk, significant results were obtained with non-fermented soy foods, but not with fermented soy foods or isoflavones [6]. In vitro evidence supports the presence of differential effects of whole soy extracts and soy isoflavones on apoptosis in PCa cells [42].